Dudakova Anna, Blei Claudia, Groß Uwe, Schulze Marco H
Institute for Medical Microbiology and Virology, University Medical Center Göttingen, Kreuzbergring 57, 37075 Göttingen, Germany.
Hospital Pharmacy, University Medical Center Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany.
Int J Infect Dis. 2022 Jun;119:150-159. doi: 10.1016/j.ijid.2022.03.054. Epub 2022 Mar 30.
Candidemia is rare and has a high mortality rate. This study analyses the impact of bedside antifungal stewardship (AFS) on clinical management and prognosis of patients with candidemia at a university hospital in Germany.
All patients with at least one positive blood culture with Candida species between 2014 and 2016 received bedside AFS with standardized recommendations. Medical records were retrospectively analyzed. Results from the intervention period from 2014-2016 (n=109), with focus on 2016 (n=39), were compared with those from the pre-intervention period in 2013 (n=30).
Bedside AFS was performed in 24/35 (69%) surviving patients in 2016 within the first 3 days after diagnosis of candidemia. All surviving patients (n=35) in 2016 received antifungal treatment compared with 24/28 (86%) in 2013 (p=0.0344). Follow-up blood cultures were performed in 25/35 (71%) in 2016 compared with 10/25 (40%) in 2013 (p=0.0046). Survival in the intervention compared with the pre-intervention group did not differ significantly (p=0.58) one year after the diagnosis of candidemia was made. However, patients with candidemia often have multiple serious comorbidities.
Individualized bedside AFS significantly improves adherence to recommendations for patients with Candida fungemia, especially guideline-oriented diagnostics and therapy. Improving the prognosis of patients with candidemia remains a huge challenge for AFS.
念珠菌血症较为罕见,死亡率较高。本研究分析了床边抗真菌管理(AFS)对德国一家大学医院念珠菌血症患者临床管理和预后的影响。
2014年至2016年间所有血培养至少有一次念珠菌属阳性的患者均接受了具有标准化建议的床边AFS。对病历进行回顾性分析。将2014 - 2016年干预期(n = 109,重点是2016年,n = 39)的结果与2013年干预前期(n = 30)的结果进行比较。
2016年,24/35(69%)存活患者在念珠菌血症诊断后的前3天内接受了床边AFS。2016年所有存活患者(n = 35)均接受了抗真菌治疗,而2013年为24/28(86%)(p = 0.0344)。2016年25/35(71%)患者进行了随访血培养,2013年为10/25(40%)(p = 0.0046)。念珠菌血症诊断后一年,干预组与干预前期组的生存率无显著差异(p = 0.58)。然而,念珠菌血症患者通常有多种严重合并症。
个体化的床边AFS显著提高了念珠菌血症患者对建议的依从性,尤其是遵循指南的诊断和治疗。改善念珠菌血症患者的预后仍然是AFS面临的巨大挑战。